Cargando…

Lenvatinib plus pembrolizumab in patients with advanced or recurrent uterine carcinosarcoma

OBJECTIVE(S): To investigate the efficacy of pembrolizumab plus lenvatinib as a second-line or later-line therapy in women with advanced or recurrent uterine carcinosarcoma (UCS). METHODS: A single-institution pharmacy database was queried for women with advanced or recurrent UCS who were prescribed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hunt, Jonathan T., Chambers, Laura M., Yao, Meng, Joehlin-Price, Amy, Debernardo, Robert, Rose, Peter G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Case Reports and Case Series
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350419/ https://www.ncbi.nlm.nih.gov/pubmed/34401435 http://dx.doi.org/10.1016/j.gore.2021.100840

Ejemplares similares

Activity of pembrolizumab and lenvatinib in mismatch repair deficient (dMMR) endometrial cancer patients who have failed pembrolizumab monotherapy: A case series
por: Rose, Peter G., et al.
Publicado: (2023)

Predictors of response to immune checkpoint inhibition in a real world gynecologic cancer population()
por: Kuznicki, Michelle L., et al.
Publicado: (2020)

Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
por: Makker, Vicky, et al.
Publicado: (2020)

Progestin and aromatase inhibitor therapy in recurrent, estrogen/progestin receptor positive uterine carcinosarcoma: A case report
por: Liang, Angela L., et al.
Publicado: (2021)

Sustained response to lenvatinib and pembrolizumab in two patients with KRAS-mutated endometrial mesonephric-like adenocarcinoma
por: Shen, Sherry, et al.
Publicado: (2021)

Tumor lenvatinib addiction and withdrawal rebound response in patients with advanced endometrial cancer
por: Lam, Clarissa, et al.
Publicado: (2023)

Response to lenvatinib and pembrolizumab combination therapy in pembrolizumab-pretreated relapsed endometrial cancer
por: Mimura, Kaito, et al.
Publicado: (2022)

Pure abscopal effect in a patient with advanced uterine carcinosarcoma
por: Okamoto, Kazuhiro, et al.
Publicado: (2023)

Modified Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab for Advanced HCC: Two Case Reports
por: Tian, Yuan, et al.
Publicado: (2023)

A case of pembrolizumab and lenvatinib as an alterntive therapy for leiomyosarcoma
por: Mehta, Naaman, et al.
Publicado: (2023)

Prolonged response of recurrent IDH-wild-type glioblastoma to laser interstitial thermal therapy with pembrolizumab
por: Hwang, Helen, et al.
Publicado: (2022)

Response to pembrolizumab in a heavily treated patient with metastatic ovarian carcinosarcoma
por: Zibetti Dal Molin, Graziela, et al.
Publicado: (2018)

Complete response to the combination of Lenvatinib and Pembrolizumab in an advanced hepatocellular carcinoma patient: a case report
por: Liu, Zhaonan, et al.
Publicado: (2019)

Long-term recurrence-free survival in a patient with stage IVB uterine carcinosarcoma
por: Yoon, Gun, et al.
Publicado: (2011)

Uterine Carcinosarcoma in a Patient with Didelphys Uterus
por: Iavazzo, C., et al.
Publicado: (2013)

Characterization and Management of Adverse Reactions in Patients with Advanced Endometrial Carcinoma Treated with Lenvatinib Plus Pembrolizumab
por: Makker, Vicky, et al.
Publicado: (2021)

Pembrolizumab plus lenvatinib in advanced endometrial cancer: case report and systematic review of lung toxicity
por: Staropoli, Nicoletta, et al.
Publicado: (2023)

Lenvatinib plus pembrolizumab a new effective combination of targeted agents
por: Perez-Fidalgo, J.A., et al.
Publicado: (2023)

Completely resolved advanced biliary tract cancer after treatment by pembrolizumab: a report of two cases
por: Alshari, Osama M, et al.
Publicado: (2019)

Pembrolizumab-induced lichenoid dermatitis treated with dupilumab
por: Park, Jonathan J., et al.
Publicado: (2023)

Tumor molecular profiling of responders and non-responders following pembrolizumab monotherapy in chemotherapy resistant advanced cervical cancer
por: Ngoi, N.Y.L., et al.
Publicado: (2018)

Carcinosarcoma of the uterine cervix arising from Müllerian ducts
por: Kim, Myounghwan, et al.
Publicado: (2015)

Port-Site Metastasis of Uterine Carcinosarcoma after Laparoscopy
por: Tan, Zhen, et al.
Publicado: (2017)

Uterine Carcinosarcoma: A Case Report and Literature Review
por: Kord, Ali, et al.
Publicado: (2020)

Clostridium and Bacteroides bacteremia as initial presentation of uterine carcinosarcoma
por: Imo, Chinonye S., et al.
Publicado: (2022)

Cost-Effectiveness of Lenvatinib Plus Pembrolizumab or Everolimus as First-Line Treatment of Advanced Renal Cell Carcinoma
por: Wang, Ye, et al.
Publicado: (2022)

A case of metastatic renal cell carcinoma successfully treated with deferred cytoreductive nephrectomy following lenvatinib plus pembrolizumab combination therapy
por: Sato, Hiroaki, et al.
Publicado: (2023)

Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
por: Finn, Richard S., et al.
Publicado: (2020)

Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma
por: Wu, Chi-Jung, et al.
Publicado: (2022)

Bullous Pemphigoid as an Adverse Reaction to Pembrolizumab: Two Case Reports
por: Thomsen, Kenneth, et al.
Publicado: (2018)

PD-1-inhibitor pembrolizumab for treatment of progressive multifocal leukoencephalopathy
por: Möhn, Nora, et al.
Publicado: (2021)

Breast metastases: A rare manifestation of advanced uterine serous carcinoma
por: McEachron, Jennifer, et al.
Publicado: (2019)

Recurrent Parotid Carcinosarcoma in an Asymptomatic Patient
por: Mansour, Joshua, et al.
Publicado: (2016)

Role of MRI in uterine didelphys with co-existing endometrial carcinosarcoma
por: McGregor, Jill, et al.
Publicado: (2018)

Uterine carcinosarcoma associated with a germline nibrin (NBN) mutation
por: Markert, Tahireh, et al.
Publicado: (2022)

Pembrolizumab and lenvatinib in recurrent ovarian clear cell carcinoma resistant to chemotherapy
por: McNamara, Blair, et al.
Publicado: (2023)

Lenvatinib Plus Pembrolizumab vs. Chemotherapy in Pretreated Patients With Advanced Endometrial Cancer: A Cost-Effectiveness Analysis
por: Feng, Mingyang, et al.
Publicado: (2022)

Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study
por: Eto, Masatoshi, et al.
Publicado: (2022)

A case of interstitial lung disease with alveolar hemorrhage induced by pembrolizumab
por: Sugano, Teppei, et al.
Publicado: (2018)

Clinical response to adding pyrotinib to pembrolizumab and lenvatinib for HER2-positive advanced intrahepatic cholangiocarcinoma: a case report
por: Zhang, Jun-Wei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_69pjiptg2rcp0alanj46dhoan0